
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharma is facing pricing and competitive headwinds in its Baqsimi product and base generics business, as well as limited visibility into the potential success of its pipeline. With an EV/2027E EBITDA of ~7x and significant stock ownership by the company's founders and directors, the stock is fairly valued at this time.
Bears say
Amphastar Pharma is facing a number of concerns, including lower selling prices for its drug Baqsimi due to higher rebates and discounts, which have led to declines in revenue and margins. Additionally, the company's pipeline development and potential new product launches are not expected until 2027, making it difficult to generate near-term growth. This, combined with ongoing competition for key products, has led to a negative outlook for the company's top-line growth and potential for a significant recovery in its stock price.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares